Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 481Head & Neck 283Thoracic 113Tumor-Agnostic 32Breast 23Other solid neoplasm 22Gynecologic 18Genitourinary 15CNS 15Sarcoma 12Dermatologic 10Other neoplasm 4Lymphoid 3Plasma cell 2Myeloid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cytarabine 905Cyclophosphamide 898fludarabine 524venetoclax 487fludarabine phosphate 468Azacitidine 459Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 229Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 204Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 163Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cetuximab × Other hematologic neoplasm × Clear all
NCT06447987 2025-12-17

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1 Recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡